Detection, isolation and uses of renalase (monoamine oxidase C)

An enzyme protein, compound technology, applied in the detection, separation and application of renal enzyme (monoamine oxidase C)

Inactive Publication Date: 2007-11-21
YALE UNIV
View PDF22 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main limitation of the activity of irreversible and non-selective MAO inhibitors is the need to adhere to the prescribed diet, because of the induction of hypertensive crisis when dietary tyramine is ingested and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection, isolation and uses of renalase (monoamine oxidase C)
  • Detection, isolation and uses of renalase (monoamine oxidase C)
  • Detection, isolation and uses of renalase (monoamine oxidase C)

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0415] The present invention includes the preparation and use of a pharmaceutical composition comprising, as an active ingredient, a compound for the treatment of arterial restenosis, adventitial fibrosis, negative remodeling, and the like. Such a pharmaceutical composition may consist of the active ingredient alone, administered to a subject in a suitable form, or the pharmaceutical composition may comprise the active ingredient together with one or more pharmaceutically acceptable carriers, one or more other ingredients or a combination of these ingredients . The active ingredient may be present in the pharmaceutical composition in the form of a physiologically acceptable ester or salt, such as in combination with a physiologically acceptable cation or anion, as is well known in the art.

[0416] As used herein, the term "pharmaceutically acceptable carrier" refers to a chemical composition combined with an active ingredient, which, after combination, is useful for administe...

Embodiment 1

[0524] Example 1: Identification and Analysis of Genes Encoding Renal Enzymes

[0525] Materials and methods

[0526] Bioinformatics analysis of MGC database

[0527]All 12,563 unique human all-ORF cDNAs used in this experiment were obtained from the Mammalian Gene Collection Project MGC and subjected to three consecutive rounds of selection. The initial MGC analysis was performed on December 24, 2001. First, select genes without GenbankDefinition for more detailed analysis. Secondly, the predicted amino acid sequences encoded by the genes selected in the first round were analyzed using BLAST (http: / / www.ncbi.nlm.nih.gov / BLAST), and those encoding proteins with less than 20% identity to known proteins were selected. those genes of the protein. Third, the presence of putative signal sequences using SignalP V2.0 (www.cbs.dtu.dk / services / SignalP-2.0 / ) and SOSUI signal Beta_Version (http: / / sosui.proteome.bio.tuat.ac.jp )assessment. Novel proteins with signal peptide sequence...

Embodiment 2

[0538] Example 2: Renal enzymes are secreted by the kidney

[0539] Construction of gene expression cassette (TAP fragment)

[0540] Using a PCR-based protocol, we added the 5′-CMV promoter and 3′-SV40pA to the 5′- and 3′-ends of each candidate clone, respectively, after two consecutive PCR reactions. The detailed methodology is described by Liang et al. Briefly, this method involves two sequential PCR steps. The first step was performed using primers (0.4 μg) containing a universal TAP end and a sequence specific for the target gene. The 5' universal end sequence was complementary to a DNA fragment containing the CMV immediate early gene promoter and was used in a second PCR step to attach the CMV promoter to the amplified gene. The 3' common end, which overlaps the DNA fragment containing the SV40 early gene transcription terminator, was also used in a second PCR step to attach the transcription terminator sequence to the amplified gene. To generate a TAP fragment contai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C.119(e) to U.S. Provisional Patent Application No. 60 / 554,552, filed March 19, 2004, and U.S. Provisional Patent Application No. 60 / 615,452, filed October 1, 2004, Both of these patent applications are hereby incorporated by reference in their entirety. [0003] Statement of Federally Sponsored Research or Development [0004] This invention was made in part with US Government funding (National Institutes of Health Grant No. K08DK 0291702), and thus the US Government has certain rights in this invention. Background of the invention [0005] Regulation of fluid and electrolyte metabolism is a major function of the kidneys. Blood enters the kidneys through the glomeruli, which filter out cells and proteins and produce a fluid with the same ionic composition as plasma fluid through a process called glomerular filtration. The glomerular filtrate then passes through a series o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/02C12N1/20C12N15/00C12Q1/00C12Q1/34C12Q1/68C12P21/06C12P21/04A61K38/44C07H21/04C07K1/00C07K16/00
Inventor 徐建朝加里・迪西尔
Owner YALE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap